| Objectives:To observe the effect of Qishenyiqi pills on TCM syndrome score,blood stasis score and platelet-related parameters and the incidence of coronary thrombosis and hemorrhage in patients with acute coronary syndromes after PCI were evaluated to explore its clinical efficacy and safety on the patients with blood stasis syndrome after PCI.Methods:60 patients qualified with acute blood syndrome after PCI who have blood stasis syndrome were selected from the chest pain center of Kunshan Traditional Chinese Medicine Hospital.The patients were randomly divided into experimental group(Qishenyiqi pill + western medicine group)30 cases and the control group(western medicine group)30 cases.The main clinical symptom scores,blood stasis score,platelet parameters(platelet aggregation rate,platelet count,platelet distribution width and mean platelet volume)and the incidence of coronary thrombosis and hemorrhage were recorded before treatment and 1 months after treatment.The clinical curative effect was observed and analyzed by SPSS 16.0.Results:The general data of the two groups,like sex,age,risk factors and previous high-risk history,no significant difference.(1)There was no significant difference between the two groups before treatment(P>0.05).The experimental group could significantly alleviate the symptoms of chest discomfort,chest pain,back pain and shortness of breath(before and after treatment were 3.73±0.98vs2.53±1.25;2.73±1.11vs0.73±0.98;2.40± 1.30vs0.33±0.48;1.33±0.76vs0.67±0.48 P<0.01),and it also could significantly improve the chest tightness,nausea and perspiration(before and after treatment were 3.47±0.86vs2.87±0.90;1.73±1.llvs1.10±1.09;2.67±1.18vs2.07±1.01 P<0.05).And the control group could significantly improve the chest pain and back pain(before and after treatment were 2.80±1.13vs1.50±1.17;2.47±1.38vs0.73±0.91 P<0.01)and alleviate the symptoms of chest discomfort(before and after treatment were 3.87±1.01vs3.20±1.32 P<0.05).Compare the two groups,the experimental group was better on chest pain.So does the chest tightness,back pain and shortness of breath.In addition,the total effective rate of the(0.73±0.98vs 1.50±1.17,P<0.01),chest discomfort,back pain and shortness of breath(2.53±1.25vs3.20±1.32;0.33±0.48 vs0.73±0.91;0.67±0.48vs1.07±0.87,P<0.05).The total effective rate of experimental group was significantly higher than that of the control group(60.00%vs 16.77%,P<0.01).(2)The continuous chest pain was significantly improved in the experimental group and the control group(before and after treatment were 8.87±2.54vs3.53 ± 3.81;8.77 ± 2.86vs4.27 ± 3.81,P<0.01).The experimental group was significantly superior to the control group in improving the tongue(2.00±1.44vs3.63±2.94,P<0.01),and the improvement of pulse and subcutaneous blood stasis in experimental group was better than that of the control group(2.40±3.73vs4.60 ± 4.40;0.53±2.03vs2.27±3.85,P<0.05).The control group couldn’t significantly improve the subcutaneous blood stasis(before and after treatment were 2.87±4.16vs2.27±3.85 P>0.05).The total scores of blood stasis syndrome in the experimental group and control group were significantly decreased(38.30±10.61 vs18.87±7.94;38.60±12.13vs25.20±10.09,P<0.01)and the experimental group was better than the control group(18.87±7.94vs25.20±10.09,P<0.01).The total effective rate of experimental group was significantly higher than that of the control group(96.67%vs 53.33%,P<0.01).(3)There was no significant difference in the platelet aggregation rate between the experimental group and the control group.It was significantly reduced after the treatment(49.93±5.44vs29.27±3.89;47.90±5.62vs31.70±3.12,P<0.01),and the experimental group was better than the control group(29.27±3.89vs31.70±3.12,P<0.01).The levels of the platelet parameters PLT was increased(170.67±17.77vs189.80±20.90,P<0.01;168.07± 13.01vs178.80±18.64,P<0.05)and MPV,PDW were decreased in both two groups(7.88±0.88vs6.21±0.83;7.72±1.07vs6.49±1.17,P<0.05 以及 14.40±1.09vs13.13±1.07,P<0.01;15.10±1.27vs14.41±1.17,P<0.05),and the decline of PDW in the experimental group was more than the control group(13.13±1.07vs14.41±1.17,P<0.05).(4)The incidence of small hemorrhage in the experimental group was less than that in the control group(6.67%vs 13.33,P<0.05).Both groups were intravascular thrombotic events and hemorrhagic events including fatal intracranial hemorrhage.Conclusion:Qishenyiqiqi pill can improve the clinical symptoms of blood stasis syndrome in patients with acute coronary syndrome after PCI.It has good antiplatelet effect and can reduce the occurrence of small hemorrhage,and does not increase the probability of the incidence of the major bleeding events including fatal bleeding and stent thrombosis. |
PDF Full Text Request